Search results
ESMO Recap: Adjuvant Vs. Neoadjuvant Therapy in Melanoma
Medscape· 6 days agoSapna Patel presented the first abstract, and it was a follow-up on some very nice work from the...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 6 days agoPhase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC ...
HOOKIPA advances HPV cancer trial with FDA nod By Investing.com
Investing.com· 5 days agoHOOKIPA Pharma Inc. (NASDAQ: HOOK), a clinical-stage biopharmaceutical company, has announced the...
NHS trials first personal skin cancer jab that can halve risk of death
The Telegraph via Yahoo News· 5 days agoIt is also undergoing early testing on other cancers. Around 70 Britons are set to take part in a...
H.C. Wainwright Cuts HOOKIPA Pharma Shares target on Narrower HB-200 Target Population By...
Investing.com· 5 days agoThe adjustment followed HOOKIPA Pharma's announcement regarding the trial design of a Phase 2/3...
BioInvent to Present Clinical Data from its Two Leading Assets at ASCO 2024
Digital Journal· 7 days ago"We are very pleased to be chosen to present data from our two lead candidates, BI-1808 (anti-TNFR2) and BI-1206 (anti-FccgRIIB) at ASCO 2024. Our research suggests that each of these first-in-class ...
U.K. Tests World-First Personalized Skin Cancer Vaccine
Forbes· 5 days agoBritish patients are trying a first-of-its-kind customized vaccine for skin cancer as part of a...
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Morningstar· 7 days agoMedia Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows a preliminary 26.9% response rate, the primary endpoint of the studyData
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Benzinga via Yahoo Finance· 7 days agoThe investigational immuno-oncology combination demonstrates an overall response rate (ORR) of 26.9%...
Treatment Options for HER2-Negative Breast Cancer
Healthline· 7 days agoMost breast cancers are HER2-negative. There are many treatment options for this type of breast cancer. Your treatment will depend on factors such as...